45 CFR § 180 compliance
C · 70
This hospital published part of what § 180 requires.
●Machine-readable file published
○Gross / standard charges
○Discounted cash price
●Payer-specific negotiated rates
●Min / max negotiated charges
●Free, public, no login required
Procedures listed
11,291
Insurances with rates
8
CPT / HCPCS codes
10,265
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $102,130 | $97,458 | $192,797 | 7 |
| J9228 | IPILIMUMAB 200 MG/40 ML (5 MG/ML) INTRAVENOUS SOLUTION | $211,865 | $102,130 | $241 | $192,797 | 24 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $55,512 | $52,972 | $104,792 | 7 |
| J2350 | OCRELIZUMAB 30 MG/ML INTRAVENOUS SOLUTION | $115,156 | $55,512 | $176 | $104,792 | 24 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $53,418 | $50,974 | $100,840 | 7 |
| J0638 | CANAKINUMAB (PF) 150 MG/ML SUBCUTANEOUS SOLUTION | $110,813 | $53,418 | $408 | $100,840 | 24 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $49,622 | $47,352 | $93,674 | 7 |
| J9309 | POLATUZUMAB VEDOTIN-PIIQ 140 MG INTRAVENOUS SOLUTION | $102,938 | $49,622 | $399 | $93,674 | 24 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $38,618 | $36,851 | $72,901 | 7 |
| J3357 | USTEKINUMAB 45 MG/0.5 ML SUBCUTANEOUS SYRINGE | $80,111 | $38,618 | $468 | $72,901 | 24 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $32,114 | $30,645 | $60,623 | 7 |
| J9042 | BRENTUXIMAB VEDOTIN 50 MG INTRAVENOUS SOLUTION | $66,619 | $32,114 | $323 | $60,623 | 24 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $31,387 | $29,951 | $59,251 | 7 |
| J9022 | ATEZOLIZUMAB 1200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $65,111 | $31,387 | $119 | $59,251 | 24 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $30,629 | $29,228 | $57,820 | 7 |
| J9119 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION | $63,539 | $30,629 | $84.63 | $57,820 | 24 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $29,895 | $28,527 | $56,434 | 7 |
| J1930 | LANREOTIDE 120 MG/0.5 ML SUBCUTANEOUS SYRINGE | $62,016 | $29,895 | $135 | $56,434 | 24 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $27,872 | $26,597 | $52,616 | 7 |
| C2642 | GAMMATILE THERAPY 11PK GT-11 | $57,820 | $27,872 | $15,953 | $52,616 | 24 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $27,689 | $26,422 | $52,270 | 7 |
| J9144 | DARATUMUMAB 1800 MG-HYALURONIDASE-FIHJ 30000 UNIT/15 ML SUBCUT SOLN | $57,439 | $27,689 | $154 | $52,270 | 24 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $26,798 | $25,572 | $50,587 | 7 |
| J9037 | BELANTAMAB MAFODOTIN-BLMF 100 MG INTRAVENOUS SOLUTION | $55,590 | $26,798 | $15,337 | $50,587 | 22 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $25,204 | $24,051 | $47,579 | 7 |
| J2997 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $52,285 | $25,204 | $274 | $47,579 | 24 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $24,144 | $23,039 | $45,577 | 7 |
| J3380 | VEDOLIZUMAB 300 MG INTRAVENOUS SOLUTION | $50,085 | $24,144 | $65.01 | $45,577 | 24 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $23,069 | $22,014 | $43,549 | 7 |
| 0795T | TCAT INS 2CHMBR LDLS PM CMPL | $47,856 | $23,069 | $13,203 | $43,549 | 22 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $23,069 | $22,014 | $43,549 | 7 |
| 0796T | TCAT INS 2CHMBR LDLS PM RA | $47,856 | $23,069 | $13,203 | $43,549 | 22 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $23,069 | $22,014 | $43,549 | 7 |
| 0797T | TCAT INS 2CHMBR LDLS PM RV | $47,856 | $23,069 | $13,203 | $43,549 | 22 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $23,069 | $22,014 | $43,549 | 7 |
| 0801T | TCAT RMV&RPL 2CHMBR LDLS PM | $47,856 | $23,069 | $13,203 | $43,549 | 22 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $23,069 | $22,014 | $43,549 | 7 |
| 0802T | TCAT RMV&RPL2CHMB LDLS PM RA | $47,856 | $23,069 | $13,203 | $43,549 | 22 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $47,856 | $23,069 | $22,014 | $43,549 | 7 |
| 0803T | TCAT RMV&RPL2CHMB LDLS PM RV | $47,856 | $23,069 | $13,203 | $43,549 | 22 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $23,021 | $21,968 | $43,458 | 7 |
| J9223 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $47,756 | $23,021 | $615 | $43,458 | 24 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $22,861 | $21,815 | $43,155 | 7 |
| J9301 | OBINUTUZUMAB 1000 MG/40 ML INTRAVENOUS SOLUTION | $47,423 | $22,861 | $98.42 | $43,155 | 24 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $45,091 | $21,736 | $20,742 | $41,033 | 7 |
| C9765 | REVASC INTRA LITHOTRIP-STENT | $45,091 | $21,736 | $12,441 | $41,033 | 22 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $45,091 | $21,736 | $20,742 | $41,033 | 7 |
| C9766 | REVASC INTRA LITHOTRIP-ATHER | $45,091 | $21,736 | $12,441 | $41,033 | 22 |
| C9767 | REVASC LITHOTRIP-STENT-ATHER | $45,091 | $21,736 | $20,742 | $41,033 | 7 |
| C9767 | REVASC LITHOTRIP-STENT-ATHER | $45,091 | $21,736 | $12,441 | $41,033 | 22 |
Showing top 50 of 11,291 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.